Key facts
- Anomer Bio’s last known valuation is $3.5M (Sep 2025).
- It has raised $450K; the latest was Seed Round ($450K) in Sep 2025.
- Notable investors include SOSV, IndieBio, Haatch, Stevenage Bioscience Catalyst.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Anomer Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Anomer Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anomer Bio
Developer of a biotech research tool designed for studying and modulating cellular sugar biology. The company's platform applies machine learning to model how sugars are processed by cells, incorporates profiling of immune interactions with glycan structures, and offers methods for validating cellular uptake and downstream functional effects, enabling researchers and pharmaceutical developers to explore sugar-mediated mechanisms of disease and discover novel therapeutic targets.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 2
- Website
- anomer.bio/
- Ownership
- Privately Held (backing)
Anomer Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anomer Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anomer Bio in its N-PORT filings yet. We sweep new filings monthly.